A Study of Xeloda (Capecitabine) as First-Line Chemotherapy in Patients With Advanced or Metastatic Gastric Cancer.
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
This single arm study will assess the efficacy and safety of Xeloda in combination with
oxaliplatin as first-line chemotherapy in patients with advanced and/or metastatic gastric
cancer who have had no prior chemotherapy for advanced or metastatic disease. Eligible
patients will receive Xeloda 1000mg/m2 po twice daily, D1-D10 every 2 weeks (10 days
treatment followed by 4 days rest period) plus oxaliplatin 85 mg/m2/day iv, D1 every 2 weeks.
The anticipated time on study treatment is until disease progression, and the target sample
size is <100 individuals.